Novo Nordisk to slash Wegovy, Ozempic U.S. list prices by up to 50%
CNBC • • business
Key Points:
- Novo Nordisk plans to reduce the U.S. list prices of its obesity and diabetes drugs, including Wegovy, Ozempic, and Rybelsus, by up to 50% starting January 1, 2027, lowering the monthly price to $675.
- The price cuts specifically target insured patients with high-deductible health plans or co-insurance arrangements, aiming to reduce their out-of-pocket costs and improve treatment accessibility.
- This strategy is expected to enhance Novo's competitiveness against Eli Lilly, which currently leads the GLP-1 market but has not significantly lowered its drug list prices.
- Patients with high-deductible plans currently pay the full list price until meeting their deductible, causing some to delay
